Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001368698 | SCV001565104 | uncertain significance | Epileptic encephalopathy | 2024-06-28 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 1101 of the FASN protein (p.Ser1101Leu). This variant is present in population databases (rs143739434, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with FASN-related conditions. ClinVar contains an entry for this variant (Variation ID: 1059422). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
ARUP Laboratories, |
RCV001810726 | SCV002049149 | uncertain significance | not provided | 2021-09-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004037052 | SCV004869695 | uncertain significance | not specified | 2022-07-06 | criteria provided, single submitter | clinical testing | The c.3302C>T (p.S1101L) alteration is located in exon 21 (coding exon 20) of the FASN gene. This alteration results from a C to T substitution at nucleotide position 3302, causing the serine (S) at amino acid position 1101 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |